One Step Further
Knee implants with innovative lattice technology closely matching native bone properties for optimised implant fixation and a durable bone foundation.
Clinical Needs &
Future of Knee Implants
“More and more patients require partial knee replacements, and it is critical to achieve a solution that does not loosen and can maintain bone quality to allow patients to continue living active, happy lives.”
Mr. Alex Liddle, DPhil FRCS(Orth)
Increasing Prevalence of Knee Osteoarthritis (OA)
1.3 million people globally receive knee replacement surgery every year, with more and more people being treated younger.
High Long-term Failure Rate of Current Implants
Existing implants see high failure rates in young patients and the leading cause of failure is loosening between the implant and bone.
Cementless Implants Fail Less
Cementless implants reduce the risk of loosening by 50% and offer long-term biologic fixation without the need for cement in the body.
Partial Knee Replacements are Better for Patients & Providers
50% of patients are suitable for partial knee replacements, which offer faster recovery and better outcomes for patients and are cost effective.
Innovation in Care
At OSSTEC, we have spent years pushing the boundaries of engineering and medical research to introduce a new generation of partial knee implant.
Our innovative fully 3D printed lattice implants mimic the porous trabecular structure of bone, allowing natural load transfer through the knee that diminishes the negative effect of stress shielding. This allows for healthier bone in the long term, leading to increased patient satisfaction and a higher quality of life.
Using next generation technology for a next generation implant, additive manufacture allows for ultimate design freedom whilst reducing waste and costs per part.
Our novel hybrid fixation features combined with the porous lattice allow for stable initial fixation as well as bone ingrowth into the implant, causing revolutionary fixation without the consequences of bone cement.
We are collaborating with the UK's leading medical institutions and organisations to develop the next generation of orthopaedic implants.
secured in VC and grant funding.
News & Updates
Keep up to date with all the latest news and updates from OSSTEC by following our LinkedIn page.
Our incredible journey in 2023
As 2024 kicks off, we're taking a moment to reflect on an incredible journey in 2023. We closed our oversubscribed investment round totalling £2M, grew our team to 8 people, unveiled our first product to the world and expanded reach in our target markets including trips to ISTA (New York), AAHKS (Dallas) and AAOS (Las Vegas). We are incredibly excited for a huge 2024!
OSSTEC Exhibit at ISTA, New York
OSSTEC had an amazing time exhibiting at International Society for Technology in Arthroplasty (ISTA), New York, in September. It was a pleasure to unveil our first product to surgeons and industry. Some key highlights include podium presentations from our team demonstrating research at OSSTEC and surgical usability sessions trialling our devices.
OSSTEC: Recognized for Excellence in Technological Innovation
OSSTEC is honored to announce nominations for three prestigious awards by the UK Business Angels Association and EISA. Our gratitude extends to the Royal Academy of Engineering and Innovate UK for their sponsorship. These nominations underscore our team's dedication to technological innovation.
OSSTEC and CEO Dr. Munford: Nominated and Awaiting Acclaim
OSSTEC is nominated for Best SEIS Investee Company 2023, showcasing our medtech innovation prowess. CEO, Dr. Maxwell Munford, is up for Entrepreneur of the Year. Gratitude to our team and partners; awaiting results with anticipation.
OSSTEC's £1.2M Funding Milestone: Paving the Way for MedTech Advancements
OSSTEC successfully closes an oversubscribed £1.2M funding round, bolstering our journey from lab to operating room with our 3D printing and biomimetic implants. This boost empowers team growth and tech development. Immense gratitude to our investors and supporters, including SFC, Parkwalk Advisors, and Embryo Ventures. More updates soon.